Eye Shingles Tied to Cancer Risk in Those With Immune Issues Herpes zoster ophthalmicus is associated with an increased risk for subsequent malignancy among individuals with an underlying history of immune dysregulation, according to a recent cohort study
Shingles Vaccine Safe in Patients With Rheumatic Diseases A herpes zoster vaccine is safe in adults with autoimmune rheumatic disease and elicits a strong immune response, but responses are weaker in those on rituximab or mycophenolate, per a phase 4 study
Zoster Vaccine Uptake Low in Rheumatic Disease in the US Recombinant zoster vaccine uptake in adults with rheumatic disease reached around 10% in the 20 months following the updated 2021 recommendations, with lack of tracking and education seen as barriers
Shingles Vaccination for Immunocompromised Adults - Medscape Shingles can recur, so people with a history of herpes zoster who are eligible for Shingrix (adults 50 years and older and immunocompromised adults 19 years and older) should receive Shingrix